Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Office of New Drugs director returns

Executive Summary

FDA Office of New Drugs Director John Jenkins returns to his position at the agency following a personal leave. OND Deputy Director Sandra Kweder served as acting director during Jenkins' absence. Kweder represented the office on the decision to request a "black box" warning on antidepressant labeling and testified on behalf of FDA at the Senate Finance Committee's hearing on the Vioxx withdrawal (1"The Pink Sheet" Oct. 18, 2004, p. 3). Jenkins represented OND on a Dec. 17 conference call on Celebrex safety data...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS045191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel